

1 **Title**

2 Full title: Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV,
3 MVA-BN-Filo Ebola vaccine regimen

4 Short title: Helminth exposure and immune response to Ebola vaccine

5

6 **Targeted journal:** PLoS Neglected Tropical Diseases

7

8 **Authors and affiliations**

9 Houreratou Barry^{1,2}, Edouard Lhomme^{2,3,4}, Mathieu Surénaud^{4,5}, Moumini Nouctara¹, Cynthia
10 Robinson⁶, Viki Bockstal^{6#}, Innocent Valea^{1,7}, Serge Somda^{1,8}, Halidou Tinto^{1,7}, Nicolas
11 Meda^{1,9}, Brian Greenwood¹⁰, Rodolphe Thiébaud^{2,3,4&*}, Christine Lacabartz^{4,5}

12

13 **Author's affiliations**

14 ¹ Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso, Burkina Faso

15 ² Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inria
16 SISTM team

17 ³ CHU Bordeaux, Department of Medical Information, Bordeaux, France

18 ⁴ Vaccine Research Institute (VRI), Créteil, France

19 ⁵ Université Paris-Est Créteil, Faculté de Médecine, INSERM U955, Team 16, Créteil, France

20 ⁶ Janssen Vaccines & Prevention B.V., Leiden, Netherlands

21 ⁷Institut de Recherche en Sciences de la Santé/Unité de Recherche Clinique de Nanoro, Burkina
22 Faso

23 ⁸Université Nazi BONI, UFR Sciences Exactes et Appliquées, Bobo-Dioulasso, Burkina Faso

24 ⁹ UFR Sciences de la santé, Université Joseph Ki Zerbo, Ouagadougou, Burkina Faso

25 ¹⁰London School of Hygiene & Tropical Medicine (LSHTM), London, UK

26 #Current affiliation : ExeVir, Ghent, Belgium

27

28 *corresponding author (RT)

29 Rodolphe.thiebaut@u-bordeaux.fr

30

31 & These authors contributed equally

32 **Abstract :**

33 **Background:** The exposure to parasites may influence the immune response to vaccines in
34 endemic African countries. In this study, we aimed to assess the association between helminth
35 exposure to the most prevalent parasitic infections, schistosomiasis, soil transmitted helminths
36 infection and filariasis, and the Ebola virus glycoprotein (EBOV GP) antibody concentration in
37 response to vaccination with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in African and
38 European participants using samples obtained from three international clinical trials.

39 **Methods/Principal Findings:**

40 We conducted a study in a subset of participants in the EBL2001, EBL2002 and EBL3001 clinical
41 trials that evaluated the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against EVD in children,
42 adolescents and adults from the United Kingdom, France, Burkina Faso, Cote d'Ivoire, Kenya,
43 Uganda and Sierra Leone. Immune markers of helminth exposure at baseline were evaluated by
44 ELISA with three commercial kits which detect IgG antibodies against schistosome, filarial and
45 *Strongyloides* antigens. Luminex technology was used to measure inflammatory and activation
46 markers, and Th1/Th2/Th17 cytokines at baseline. The association between binding IgG antibodies
47 specific to EBOV GP (measured on day 21 post-dose 2 and on Day 365 after the first dose
48 respectively), and helminth exposure at baseline was evaluated using a multivariable linear
49 regression model adjusted for age and study group.

50 Seventy-eight (21.3%) of the 367 participants included in the study had at least one helminth
51 positive ELISA test at baseline, with differences of prevalence between studies and an increased
52 prevalence with age. The most frequently detected antibodies were those to *Schistosoma mansoni*
53 (10.9%), followed by *Acanthocheilonema viteae* (9%) and then *Strongyloides ratti* (7.9%). Among
54 the 41 immunological analytes tested, five were significantly ($p < .003$) lower in participants with
55 at least one positive helminth ELISA test result: CCL2/MCP1, FGFbasic, IL-7, IL-13 and
56 CCL11/Eotaxin compared to participants with negative helminth ELISA tests. No significant
57 association was found with EBOV-GP specific antibody concentration at 21 days post-dose 2, or
58 at 365 days post-dose 1, adjusted for age group, study, and the presence of any helminth antibodies
59 at baseline.

60 **Conclusions/Significance:** No clear association was found between immune markers of helminth
61 exposure as measured by ELISA and post-vaccination response to the Ebola Ad26.ZEBOV/MVA-
62 BN-Filo vaccine regimen.

63 **Keywords:** Helminth pre-exposure; Ebola vaccine; immune response

64 **Author Summary**

65 Recurrent exposure to parasites may influence the immune response to vaccines, especially in
66 endemic African countries. In this study we aimed to assess the association between immune
67 markers of helminth exposure and the immune response post-vaccination with the Ad26.ZEBOV,
68 MVA-BN-Filo Ebola vaccine regimen in African and European participants who participated in
69 three international clinical trials. Seventy-eight (21.3%) of the 367 participants included in the
70 study, had at least one helminth ELISA positive test at baseline with differences of prevalence
71 between studies and an increased prevalence with increasing age. After adjustment for
72 confounding factors, the study did not show a clear association between immunological markers
73 of helminth exposure and the antibody concentration in response to the Ebola vaccine regimen.

74

75 **Conflict of interest statement**

76 Viki Bockstal and Cynthia Robinson were full-time employees of Janssen Vaccines and
77 Prevention at the time of the study and may hold shares of Johnson & Johnson.

78

79 **Data availability**

80 Janssen has an agreement with the Yale Open Data Access (YODA) Project to serve as the
81 independent review panel for the evaluation of requests for clinical study reports and participant-
82 level data from investigators and physicians for scientific research that will advance medical
83 knowledge and public health. Data will be made available following publication and approval by
84 YODA will be considered of any formal request with a defined analysis plan. For more information
85 on this process or to make a request, please visit the Yoda Project site at <http://yoda.yale.edu>. The
86 data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at
87 <https://www.janssen.com/clinical-trials/transparency>.

88

89

90

91

92

93 **Introduction**

94 Since its discovery in the Democratic Republic of Congo (DRC) in 1976, the Ebola virus has
95 emerged periodically and infected people in several African countries with a high mortality and
96 morbidity rate [1]. The major outbreak of 2014-2016 in West Africa led to the acceleration of
97 vaccine development against EVD and two Ebola vaccines (the rVSV vaccine developed by Merk
98 and Ad26.ZEBOV, MVA-BN-Filo developed by Janssen) have now been prequalified by the
99 WHO and have been used in recent Ebola outbreaks [2-4].

100 Before its licensure, the heterologous two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine
101 regimen was evaluated in several clinical trials including phase 1, 2 and 2b trials in the USA,
102 Africa and Europe [5-12]. Although, the results showed the vaccine regimen to be immunogenic,
103 some geographic variabilities of the immune response were found and these variabilities are not
104 yet explained [13]. In the phase 1 trials conducted in Europe and East Africa, one year after dose
105 1 immunization, the antibody concentrations of European subjects were statistically significantly
106 higher than those of East African subjects, with the European mean value being 23% higher than
107 the East African one [13].

108 The observed lower level in induced immune responses in African countries compared to Europe
109 could be explained by several factors such as human genetic, environmental, or demographic
110 factors. One possible explanation is that recurrent exposure to the parasitic infections that are
111 prevalent in African countries could explain such a decrease [14]. Indeed, studies in both human
112 and animal models have shown that trematode, nematode, and *Plasmodium* infections can lead to
113 decreased efficacy of previous vaccination and an inability to ward off new infection [15-18].

114 Helminth infections may induce a strong T helper (Th2) 2 response, in addition to inducing
115 regulatory T cells, anti-inflammatory cytokines and other mechanisms that modulate the overall
116 immune response [19-21]. A recent paper shows lower HIV-specific ADCC antibody in people
117 infected with *S. mansoni* [22]. Many studies have suggested that an activated immune
118 microenvironment prior to vaccination may impede the immune response to vaccines. Muyanja et
119 al [23], found in a study conducted in Entebbe, Uganda and Lausanne, Switzerland that immune
120 activation alters cellular and humoral responses to yellow fever 17D (YF-17D) vaccine in an
121 African cohort. They found that YF-17D-induced CD8+ T cell and B cell responses were
122 substantially lower in immunized individuals from Entebbe compared with immunized individuals
123 from Lausanne. The impaired vaccine response was associated with reduced YF-17D replication

124 and higher frequencies of exhausted and activated NK cells, differentiated T and B cell subsets
125 and proinflammatory monocytes suggesting an activated immune microenvironment in the
126 Entebbe volunteers. Another study that examined the relationship between monocytes and natural
127 killer cells with age, HIV infection and influenza vaccine responses showed a deleterious effect of
128 inflammatory monocytes on antigen-specific vaccine response in HIV infection [24].

129 In Africa, the major soil-transmitted helminth (STH) infections, hookworm (*Necator americanus*
130 and *Ancylostoma duodenale*), large roundworms (*Ascaris lumbricoides*), and whipworms
131 (*Trichuris trichiura*) are often co-endemic with schistosome infections, in particular *Schistosoma*
132 *mansoni* [25,26]. Since 2007, the WHO and its partners have been mobilizing resources and
133 working together to achieve control and elimination of helminths infection. Although some
134 progress has being made, the prevalence of helminth infections remains high in some parts of sub-
135 Saharan Africa. Prevalence varies substantially from one country to another and also within
136 country. STH prevalence in Africa ranges between 5% to 20% and Schistosomiasis varies between
137 10% to 60% [14, 27-33].

138 There is still limited scientific evidence that exposure to helminths infections can have an impact
139 on either the immediate response to vaccination or the durability of the response, and there are no
140 data yet in the case of Ebola vaccines, though it is mainly intended for populations living in areas
141 endemic for helminth infections. Demonstrating a link between helminths infections and the
142 response to vaccine could impact vaccination programmes and raise awareness of the need for
143 better management of helminth infections in endemic countries. The main objective of this study
144 was to assess the association between the immune markers of helminth exposure at baseline to the
145 Ebola virus glycoprotein (EBOV GP) antibody concentration post-vaccination (21 days post dose
146 two and D365 post first vaccination) in African participants from clinical studies EBL2002 and
147 EBL3001 and European participants from clinical study EBL2001 who received an Ad26.ZEBOV,
148 MVA-BN-Filo vaccine regimen against Ebola virus disease. We hypothesized that the immune
149 response to the helminths could be a marker negatively associated with the response to the Ebola
150 vaccine. The secondary objectives of the study were to evaluate the association between
151 inflammatory/activation factors measured at baseline and the EBOV GP antibody concentration
152 post-vaccination and to evaluate the association between helminth infections with hyper-
153 eosinophilia at baseline and EBOV GP antibody concentration post-vaccination in the same
154 population as eosinophilia is thought to be a marker of helminth infection [34].

155 **Methods**

156 **Study design**

157 We conducted a cross sectional study in a subset of participants in the EBL2001, EBL2002 and
158 EBL3001 trials in which HIV-negative participants received an active Ebola vaccine regimen
159 consisting of Ad26.ZEBOV as dose 1 followed by MVA-BN-Filo as dose 2 [5-12]. All participants
160 were HIV-negative. EBL2001 and EBL2002 were both phase 2 randomised, observer-blind,
161 placebo-controlled studies in which participants received intramuscular injections of
162 Ad26.ZEBOV, followed 28, 56 or 84 days later by MVA-BN-Filo. In the EBL2001 study
163 (ClinicalTrials.gov Identifier: NCT02416453 and EudraCT 2015-000596-27), 18 to 65 years old
164 healthy adults were included in the United Kingdom and France. The EBL2002 study
165 (ClinicalTrials.gov Identifier: NCT02564523) was conducted in Burkina Faso, Cote d'Ivoire,
166 Kenya and Uganda and enrolled three cohorts; 18 to 70 years old healthy adults, HIV infected
167 adults, 12 to 17 years old adolescents and 6 to 11 years old children. The EBL3001
168 (ClinicalTrials.gov Identifier: NCT02509494) was a phase 3 double-blinded study which
169 evaluated the safety and immunogenicity of the Ad26.ZEBOV (at day 0) and MVA-BN-Filo (at
170 day 56) vaccine regimen in healthy adults, adolescents, children and toddlers in Sierra Leone.
171 The Phase 2 UK/France study (EBL2001) protocol and study documents were approved by the
172 French national Ethics Committee (CPP Ile de France III; 3287), the French Medicine Agency
173 (150646A-61), the UK Medicines and Healthcare Products Regulatory Agency (MHRA), and the
174 UK National Research Ethics Service (South Central, Oxford; A 15/SC/0211). The Phase 2
175 Kenya/Uganda/Burkina Faso/Côte d'Ivoire study (EBL2002) protocol and study documents were
176 approved by local and national independent Ethics Committees and Institutional Review Boards
177 of the participating countries. The Sierra Leonean Phase 2 study (EBL3001) protocol and study
178 documents were approved by the Sierra Leone Ethics and Scientific Review Committee, the
179 Pharmacy Board of Sierra Leone, and the London School of Hygiene & Tropical Medicine ethics
180 committee. Participants included in the present study were randomly sampled from the initial
181 clinical trials.

182 **Ebola binding antibody assay**

183 The Ebola binding antibody concentration was assessed as a primary or secondary endpoint of
184 the three studies as previously described [5-12]. EBOV GP-specific binding antibodies were
185 measured at all timepoints using an EBOV GP Filovirus Animal Non-Clinical Group (FANG)

186 enzyme-linked immunosorbent assay (ELISA) performed at Q2 Solutions (San Juan Capistrano,
187 CA, USA). For this substudy, IgG binding antibodies specific to EBOV GP at Day 21 post-dose
188 2, and on Day 365 after the first dose were the two endpoints considered.

189 **Helminth ELISA testing**

190 A subset of the remaining baseline serum samples (pre vaccination) from the three trials'
191 participants has been used for analysis of helminth IgG and inflammation and activation markers.
192 Helminth IgG was evaluated by ELISA with three commercial kits (ELISA *Schistosoma mansoni*,
193 Bordier®; ELISA *Acanthocheilonema viteae*, Bordier®; ELISA *Strongyloides ratti*, Bordier®) to
194 measure baseline IgG against the pathogens causing schistosomiasis, strongyloidiasis and filariasis
195 respectively (Appendix 1 - table S1).

196 The assays were performed following manufacturer's instructions. Absorbance at 405 nm was read
197 using an ELISA microplate reader. Results were expressed as the ratio of the optical density (OD)
198 of each sample to the OD of the "threshold" sample supplied in each kit. Samples with a ratio > 1
199 were considered positive. For all the ratios between 0.9 and 1.1, the measurement was repeated to
200 confirm the result. If the result was discordant, a third replicate was performed.

201 Eosinophilia was defined as a blood eosinophil count higher than 500/ mm³ and hyper eosinophilia
202 as an eosinophil level higher than 1000/mm³. Eosinophil counts were available only for studies
203 EBL2001 and EBL2002.

204 **Inflammation/activation markers**

205 Luminex technology with commercial kits (Human XL cytokine discovery premixed magnetic
206 Luminex Perf assay kit 41plex, R&D systems) was used to measure inflammatory and activation
207 markers, and Th1/Th2/Th17 cytokines at baseline prior to vaccination. The following 41 markers
208 were measured: CCL2/MCP-1, CCL4/MIP-1 β , CCL19/MIP-3 β , CD40L/TNFSF5, CXCL10/IP-
209 10, FGF-basic, G-CSF, GRZ B, IFN- β , IL-1 α /IL-1F1, IL-1-ra/IL-1F3, IL-3, IL-5, IL-7, IL-10, IL-
210 13, IL-17A, B7-H1/PD-L1, TNF- α , VEGF, CCL3/MIP-1 α , CCL11/Eotaxin, CCL20/MIP-3 α ,
211 CX3CL1/Fractalkine, EGF, Flt-3L, GM-CSF, IFN- α , IFN- γ , IL-1 β /IL-1F2, IL-2, IL-4, IL-6, IL-
212 8/CXCL8, IL-12p70, IL-15, IL-33, TGF- α , TRAIL, CCL5/RANTES and IL-17E/IL25. Results
213 were expressed as concentration of each analyte (pg/ml). We included results with extrapolated
214 data (data lower than the last range point, but whose concentration was still calculated by the
215 analysis software). For data below the last range point for which the concentration could not be
216 calculated (<OOR), we imputed the lowest value obtained.

217 **Statistical aspects**

218 *Sample size*

219 For the sample size calculation, we assumed a 25% prevalence of helminth exposure at baseline
220 among African participants as the ELISA could detect both past and current infections. For a
221 prevalence of 25%, a total of 28, 24 and 41 participants who had received MVA-BN-Filo at 28, 56
222 and 84 days post Ad26.ZEBOV, respectively, were needed to demonstrate a minimum difference
223 of antibody titre of 0.56 (on log-scale) between participants positive for helminths exposure
224 compared to those who were antibody negative with a statistical power of 80% and alpha risk of
225 5%. This minimum difference corresponds to the interquartile range observed at D21 post dose 2
226 in the EBL2002 study among participants who received dose 2 at D56 post dose 1. The sample
227 size calculations were performed in regards to the primary hypothesis to be tested for each study
228 separately (see more details in Appendix 2).

229 *Statistical analyses*

230 Spearman correlations were performed between the concentration of inflammatory and activation
231 markers measured at baseline and the EBOV GP antibody concentration 21 days post-dose 2 and
232 365 days post-dose 1 vaccination, respectively. The association between the immune response to
233 helminths and the levels of activation of inflammatory markers was assessed using a Student's t-
234 test. The association between the immune response to helminths and eosinophil count, was
235 assessed by the Chi square test. The association between EBOV GP antibodies and eosinophil
236 count was assessed by Pearson correlation and a mean comparison of the concentration of EBOV
237 GP antibodies with normal eosinophilia (<500/mm³) or hyper-eosinophilia (level >500/ mm³) was
238 performed using a Student's t-test.

239 The association between the concentration of EBOV GP antibodies 21 days post-dose 2 or 365
240 days post-dose 1, and positive ELISA for helminth exposure at baseline (ELISA *S. mansoni*,
241 ELISA *A. viteae*, ELISA *S. ratti*) was evaluated by study (EBL2001, EBL2002 and EBL3001), in
242 the pooled studies for any ELISA test (considered positive if at least one of the three tests was
243 positive) and for each of the three ELISA tests separately using Student's t-test. Linear regression
244 models with the log transformed concentration of EBOV GP antibodies at either 21 days post-dose
245 2 or at 365 day post-dose 1 as the dependant variable were used to adjust for potential confounding
246 factors (age group and study). We analyzed the immune response to helminth exposure as a five
247 modalities variable: no positive test (modality 1), a single positive test (modality 2-4), or multiple

248 positive tests (modality 5). All analyses were conducted using RStudio version 1.2.5033 and a p-
 249 value ≤ 0.05 was considered as statistically significant.

250 Results

251 Study population

252 A total of 367 participants was included in the analyses: 87 (23.7%) from EBL2001, 184 (50.1%)
 253 from EBL2002 and 96 (26.2%) from EBL3001. Study population characteristics (sex, age,
 254 country) are described in **Table1**.

255 **Table1: Description of the population included in the helminth substudy by trial (EBL2001,**
 256 **EBL2002, EBL3001)**

Characteristics	Pooled studies (<i>N</i> = 367)	EBL2001 (Europe) (<i>N</i> = 87)	EBL2002 (East and West Africa) (<i>N</i> = 184)	EBL3001 (Sierra Leone) (<i>N</i> = 96)
Sex, n (%)				
Female	167 (45.5%)	46 (52.8%)	83 (45.1%)	38 (39.6%)
Males	200 (54.5%)	41 (47.2%)	101 (54.9%)	58 (60.4%)
Age, years				
median (Q1, Q3)	19 (10, 3)	40 (30, 5)	16 (11, 3)	10 (4, 2)
Adults, n (%)	192 (52.3%)	87 (100.0%)	81 (44.0%)	24 (25.0%)
Adolescents, n (%)	72(19.6%)	0 (0.0%)	49 (26.6%)	23 (24.0%)
Children, n (%)	103(28.1%)	0 (0.0%)	54 (29.3%)	49 (51.0%)
Country, n (%)				
France	34 (9.3%)	34 (39.1%)	-	-
United Kingdom	53 (14.4%)	53 (60.9%)	-	-
Burkina Faso	55 (15.0%)	-	55 (29.9%)	-
Cote d'Ivoire	37 (10.1%)	-	37 (20.1%)	-
Kenya	42 (11.4%)	-	42 (22.8%)	-
Uganda	50 (13.6%)	-	50 (27.2%)	-
Sierra Leone	96 (26.2%)	-	-	96 (100.0%)

257

258 **Prevalence of helminth exposure at baseline**

259 A total of 78 participants (21.3%) had at least one positive helminth ELISA test at baseline,
260 including 20 (5.45%) participants with at least two positive helminth ELISA tests and 4 (1.1%)
261 participants with all three helminth ELISA tests positive. *S. mansoni* was the most frequent
262 helminth infection detected (40 participants, 10.9%). 33 participants (9.0%) and 29 participants,
263 7.9%) had positive ELISA tests to *A. viteae* and *S. ratti* respectively. The prevalence of helminth
264 ELISA test positivity is shown in **Fig 1 and Appendix 3-Table S3**

265

266 **Fig 1. Description of helminth ELISA tests results at baseline among the 367 participants from**
267 **EBL2001, EBL2002 and EBL3001 trials.**

268 Elisasr: This line shows the 29 samples which were positive in the *S. ratti* ELISA test

269 Elisaav: This line shows the 3 samples which were positive in the *A. viteae* ELISA test

270 Elisasm: This line shows the 40 samples which were positive in the *S. mansoni* ELISA test

271 The intersection size on the y axis shows the number of samples which were positive for the tests indicated with dots (single test) or dots and lines
272 (multiple tests) below the x axis.

273 Each bar shows the number of samples positive to each test taken alone and the number of samples positive to all the possible combination of the
274 tests.

275

276 The distribution of the type of helminth by age group, study and country is shown in **Table 2**. The
277 positive rate increased with age with 26% (50/192) of adults, 18% (13/72) of adolescents and 15%
278 (15/103) of children having at least one positive helminth ELISA test ($p = 0.05$). No significant
279 difference was found between males (37/200, 18%) and females (41/167, 25%) ($p = 0.20$). Adults
280 represented 64% of all participants with at least one positive ELISA test. More participants had at
281 least one positive helminth ELISA test in EBL2002 study (47/184, 26%) and in the EBL3001 study
282 (22/96, 23%) as compared to the EBL2001 study (9/87, 10%). The highest positive rate was found
283 in Uganda (34%) followed by Cote d'Ivoire (32%), Burkina Faso (25%) then Sierra Leone (23%).
284 The lowest rates of any positive helminth ELISA test were found in England (9.4%), Kenya
285 (9.5%), and France (12%). Results are shown in **Appendix 3-Tables S4 and S5**.

286

287

288

289

290

291

292

293

294 **Table 2: Distribution of the type of helminth by age group(cohort), study and country.**

295

Characteristic	None, N = 289	<i>A.vitae</i>¹, N = 17	<i>S.mansoni</i>¹, N = 27	<i>S.ratti</i>¹, N = 14	Multiple², N = 20	Overall, N = 367
AGE GROUP, n (%)						
Children	88 (85%)	4 (3.9%)	4 (3.9%)	1 (1.0%)	6 (5.8%)	103 (100%)
Adolescents	59 (82%)	3 (4.2%)	5 (6.9%)	1 (1.4%)	4 (5.6%)	72 (100%)
Adults	142 (74%)	10 (5.2%)	18 (9.4%)	12 (6.2%)	10 (5.2%)	192 (100%)
SEX						
Female	126 (75%)	11 (6.6%)	12 (7.2%)	9 (5.4%)	9 (5.4%)	167 (100%)
Male	163 (82%)	6 (3.0%)	15 (7.5%)	5 (2.5%)	11 (5.5%)	200 (100%)
STUDY, n (%)						
EBL2001	78 (90%)	1 (1.1%)	1 (1.1%)	6 (6.9%)	1 (1.1%)	87 (100%)
EBL2002	137 (74%)	14 (7.6%)	18 (9.8%)	7 (3.8%)	8 (4.3%)	184 (100%)
EBL3001	74 (77%)	2 (2.1%)	8 (8.3%)	1 (1.0%)	11 (11%)	96 (100%)
COUNTRY, n (%)						
Burkina Faso	41 (75%)	2 (3.6%)	10 (18%)	0 (0%)	2 (3.6%)	55 (100%)
Cote Ivoire	25 (68%)	2 (5.4%)	4 (11%)	2 (5.4%)	4 (11%)	37 (100%)
France	30 (88%)	1 (2.9%)	0 (0%)	2 (5.9%)	1 (2.9%)	34 (100%)
United Kingdom	48 (91%)	0 (0%)	1 (1.9%)	4 (7.5%)	0 (0%)	53 (100%)
Kenya	38 (90%)	0 (0%)	2 (4.8%)	2 (4.8%)	0 (0%)	42 (100%)
Sierra Leone	74 (77%)	2 (2.1%)	8 (8.3%)	1 (1.0%)	11 (11%)	96 (100%)
Uganda	33 (66%)	10 (20%)	2 (4.0%)	3 (6.0%)	2 (4.0%)	50 (100%)

296 ¹Positive ELISA test for only this specific helminth test

297 ²Multiple positive ELISA tests (a combination of at least two positive helminth ELISA tests)

298 **Eosinophil level at baseline**

299 Only 18 participants were found with eosinophilia (an eosinophil count higher than 500 cells /
300 mm³ at baseline, all from the EBL2002 study. Among them, 9 (50%) had at least one positive
301 helminth ELISA test. More participants with at least one positive helminth ELISA test had
302 eosinophilia (9/55, 16.4%) than participants with negative helminth ELISA tests (9/213, 4.2%) (p
303 = 0.003, Appendix 4 - tables S6 to S8). No association was found between EBOV-GP antibody
304 levels and the presence of eosinophilia ($p = 0.56$, Appendix 4 - Figure S1).

305

306 **Inflammatory markers at baseline**

307 The distributions of the inflammatory/activation markers as measured by Luminex were
308 significantly different between studies, with a general increase of inflammatory and activation
309 markers (i.e. CCL19/MIP-3 β , TRAIL, CCL4/MIP-1 β , CXCL10/IP-10, IL-6, IL-1ra, IL-3, IL-5,
310 IL-10, IL-17A, TNF α , IL-33, TGF α , CCL5/RANTES, PD-L1, VEGF, MIP-1 α , MIP-3 α ,
311 CX3CL1) in African trials (EBL2002, EBL3001) as compared to the trial conducted in Europe
312 (EBL2001). All results are provided in supplementary Appendix 5- Figure S4.

313 None of the inflammatory and activation markers measured at baseline were correlated with
314 EBOV GP antibody concentration, either at 21 days post dose 2 (Appendix 5 - Figure S2A), or
315 at 365 days post dose 1 (Appendix 5 - Figure S2B). Among the 41 analytes tested, 5 were
316 significantly lower in participants with at least one positive helminth ELISA test compared to
317 those without any positive test: IL-13 ($p = 0.008$), CCL11/Eotaxin ($p = 0.002$), IL-7 ($p = 0.004$),
318 CCL2/MCP-1 ($p = 0.002$), and basic FGF ($p = 0.002$) (Appendix 5 - Figure S3).

319 **EBOV-GP antibody concentration at Day 21 post-dose two**

320 In the pooled univariable analysis (Table 3), the EBOV-GP antibody concentration 21 days post-
321 dose 2 was not significantly associated with any helminth ELISA tests (any Helminth, $p=0.07$).
322 although EBOV-GP antibody concentrations tended to be lower in participants with an *A. viteae*
323 positive ELISA test compared to those without any positive ELISA (-0.61 log units/ml, 95%
324 CI: -1.13 – -0.09). The EBOV-GP antibody concentration at 21 days post dose 2 was significantly
325 different according to age groups ($p = 0.002$). Children had a higher EBOV-GP binding antibody
326 GMC at Day 21 post-dose 2 than adults (+0.45 log unit/ml, 95% CI: 0.20 – 0.70).

327 A multivariable analysis adjusted for age group and the study was performed. There was no
328 association between helminth ELISA seropositivity and EBOV-GP antibody concentration at 21

329 days post-dose 2 ($p = 0.19$). Age group was still associated with antibody concentration with a
 330 higher EBOV-GP antibody concentration at 21 days post dose 2 in children compared to adults
 331 (+0.42 log unit/ml, 95% CI: 0.12 – 0.73).

332 **Table 3: Results of univariable and multivariable linear regression analysis of EBOV-GP antibody**
 333 **concentration (log₁₀ transformed) at 21 days post dose 2 adjusted for helminth ELISA test, age**
 334 **group and study**

Variables	Univariable analysis			Multivariable analysis		
	Coefficient	p-value	95% CI	Coefficient	p-value	95% CI
Any helminth (Yes vs No)	-0.24	0.07	-0.51 – 0.02			
Helminth		0.18			0.19	
None	ref					
<i>A. viteae</i>	-0.61	0.02	-1.13 – -0.09	-0.60	0.02	-1.12 – -0.08
<i>S. mansoni</i>	-0.15	0.47	-0.57 – 0.26	-0.10	0.64	-0.53 – 0.32
<i>S. ratti</i>	-0.02	0.95	-0.5 – 0.55	0.11	0.70	-0.46 – 0.68
Multiple¹	-0.22	0.37	-0.69 – 0.26	-0.22	0.37	-0.70 – 0.27
Age group		0.002			0.02	
Adults	ref			ref		
Children	0.45	0.0004	0.20 – 0.70	0.42	0.006	0.12 – 0.73
Adolescent	0.20623	0.15	-0.07 – 0.49	0.17	0.29	-0.15 – 0.49
Study		0.23			0.57	
EBL2001	ref			ref		
EBL2002	0.20	0.14	-0.07 – 0.47	0.09	0.58	-0.23 – 0.40
EBL3001	0.25	0.11	-0.05 – 0.55	0.03	0.86	-0.34 – 0.41

335 ¹Multiple positive ELISA tests (a combination of at least two positive helminth ELISAs tests)

336 **EBOV-GP antibody concentration at Day 365 post-dose 1 vaccination**

337 The univariable and multivariable analyses of the EBOV GP antibody concentration at Day 365
 338 found no significant association with helminth exposure (Table 4). However, age group and study
 339 were independently associated with the EBOV-GP antibody concentration. Adolescence exhibited
 340 a better response as compared to children (-0.41 log unit/ml, 95% CI: -0.73 – -0.09). Even after
 341 adjustment for helminth exposure and age, the participants included in Europe had a better
 342 response than in Africa ($p < 0.001$).

343 **Table 4: Results of the univariable and multivariable analysis of EBOV-GP antibody concentration**
 344 **(log₁₀ transformed) at 365 days post-dose 1 vaccination, adjusted for helminth ELISA test, age group**
 345 **and study**

Variables	Univariable analysis			Multivariable analysis		
	Coefficient	p-value	95% CI	Coefficient.	p-value	95% CI
Any helminth (Yes vs No)	-0.17	0.23	-0.45 – 0.11			
Helminth		0.18			0.85	
None	ref			ref		
<i>A.vitea</i>	-0.06	0.82	-0.60 – 0.48	-0.13	0.61	-0.64 – 0.38
<i>S. mansoni</i>	-0.18	0.42	-0.61 – 0.26	-0.10	0.64	-0.52 – 0.32
<i>S. ratti</i>	0.16	0.60	-0.45 – 0.78	-0.09	0.77	-0.67 – 0.50
Multiple¹	-0.48	0.06	-0.98 – 0.02	-0.24	0.32	-0.72 – 0.24
Age	0.01	0.003	0.004 – 0.01			
Age group		0.005			0.03	
Adults	ref			ref		
Children	-0.22	0.11	-0.49 – 0.02	0.12	0.41	-0.17 – 0.42
Adolescent	-0.52	0.001	-0.82 – -0.21	-0.28	0.08	-0.60 – 0.03
Study		<0.001			<0.001	
EBL2001	ref					
EBL2002	-0.50	0.003	-0.82 – 0.17	-0.44	0.02	-0.81 – -0.07
EBL3001	-1.17	<0.001	-1.53 – -0.81	-1.15	<0.001	-1.56 – -0.73
Country		<0.001				
United Kingdom	ref					
Burkina Faso	-0.48	0.05				
Cote d’Ivoire	-0.74	0.005				
France	-0.41	0.16				
Kenya	- 0.85	0.001				
Sierra Leone	-1.37	<0.001				
Uganda	-0.77	0.002				

346 ¹Multiple positive ELISA tests (a combination of at least two positive helminth ELISAs)

347

348 **Discussion**

349 As expected, the prevalence of helminth exposure as indicated by detection of antibodies against
350 *S.mansoni*, *A viteae* and *S rattii* varied according to geographical location, and increased with age.
351 Helminth exposure did not impact the EBOV-GP antibody concentration post Ad26.ZEBOV,
352 MVA -BN-Filo vaccination, neither at 21 days post-dose 2, nor one-year post-dose 1.

353 The three ELISA tests used in our study allowed us to estimate exposure to the main helminths
354 responsible for schistosomiasis, soil transmitted helminth infections (*Strongyloides*) and filariasis.
355 A positive helminth ELISA test revealed the presence of antibodies against the targeted helminth
356 species that could be the result of a recent or past exposure. Therefore, we may have missed the
357 association if only recent or ongoing exposure to an helminth has an impact on the immune
358 response to the vaccine.

359 We used the eosinophil count as an indirect measure of recent exposure to helminth infection.
360 However, the prevalence of hyper-eosinophilia was very low, which is consistent with a low
361 prevalence of current or recent infection in helminth-exposed participants in our study. As many
362 pathological conditions can lead to eosinophilia, the common causes being allergies, drug reactions
363 and parasitosis, it remains an imperfect marker to evaluate a recent helminth infection. The
364 limitation of using these ELISA tests is the existence of high level of cross-reactivity between the
365 ELISA assays and with other helminths. There could be an association with a specific infection that
366 these broad-based assays might not have picked up.

367 Other parasites not measured in our study could also play a role in modulating the immune
368 response in Africa such as malaria [35-38]. However, Ishola D et al [38] did not find a consistent
369 effect of malaria infection on EBOV-GP binding antibody concentrations assessed post-dose 2
370 vaccination with the Ad26.ZEBOV, MVA-BN-Filo regimen in Sierra Leone, but they did observe
371 a trend toward lower vaccine-induced antibody concentrations (GMR, 82; 95% CI, .67–1.02) in
372 participants with malaria infection as measured by microscopy.

373 A majority of the activation/inflammation biomarkers quantified in this study were increased at
374 baseline in individuals enrolled in African trials (EBL2002 and 3001) as compared to the European
375 trial (EBL2001). This observation is consistent with what was already described in the literature
376 [39-41]. However, we did not observe any correlation between anti-EBOV GP antibody response
377 and any of the biomarkers measured at baseline. Other markers not quantified in this study and
378 more specific of antibody responses, like IL-21, CXCL13, BAFF and APRIL, could be different

379 in African and European individuals. Helminth exposure, as measured in this study, did not seem
380 to be associated with activation/inflammation markers and showed a decrease of IL-13,
381 CCL11/Eotaxin, IL-7, CCL2/MCP-1 and bFGF. Thus, these results are consistent with the absence
382 of an effect of helminth exposure on the level of anti-EBOV GP antibody response observed after
383 vaccination.

384 In conclusion, the results of the present study do not suggest an association between the immune
385 response to helminths exposure and the response to the Ad26.ZEBOV, MVA-BN-Filo vaccine
386 regimen. Direct measurement of the microbiota present at the time of vaccination may provide
387 additional information on the potential factors associated with variation in the response to
388 vaccines in Africa [42].

389
390
391
392
393
394

395 **Acknowledgment**

396 This project received funding from the Innovative Medicines Initiative 2 Joint Undertaking under
397 grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861) and EBOVAC3
398 (grant nr.800176). This Joint Undertaking receives support from the European Union's Horizon
399 2020 research and innovation programme and the EFPIA.

400

401 References

402

- 403 1. Malvy D, McElroy AK, de Clerck H, Günther S, van Griensven J. Ebola virus
404 disease. *The Lancet* [Internet]. 2019 Mar [cited 2023 Feb 1];393(10174):936–48.
405 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0140673618331325>
406
- 407 2. World Health Organization. WHO prequalifies Ebola vaccine, paving the way for
408 its use in high-risk countries. [cited 2021 Mar 25]. Available from:
409 [https://www.who.int/news-room/detail/12-11-2019-who-prequalifies-ebola-vaccine-](https://www.who.int/news-room/detail/12-11-2019-who-prequalifies-ebola-vaccine-paving-the-way-for-its-use-in-high-risk-countries)
410 [paving-the-way-for-its-use-in-high-risk-countries.](https://www.who.int/news-room/detail/12-11-2019-who-prequalifies-ebola-vaccine-paving-the-way-for-its-use-in-high-risk-countries)
411
- 412 3. World Health Organization. Strategic Advisory Group of Experts (SAGE) on
413 immunization interim recommendations on vaccination against Ebola Virus
414 Disease (EVD) 7 May 2019. [cited 2021 Mar 25]. Available from:
415 [https://www.who.int/immunization/policy/position_papers/interim_ebola_recommendati](https://www.who.int/immunization/policy/position_papers/interim_ebola_recommendations_may_2019.pdf?ua=1)
416 [ons_may_2019.pdf?ua=1.](https://www.who.int/immunization/policy/position_papers/interim_ebola_recommendations_may_2019.pdf?ua=1)
417
- 418 4. Vaccine against Ebola: Commission grants new market authorizations. [cited
419 2021 Mar 25]. Available from:
420 https://ec.europa.eu/commission/presscorner/detail/en/IP_20_1248
421
- 422 5. Pollard AJ, Launay O, Lelievre JD, Lacabaratz C, Grande S, Goldstein N, et al.
423 Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-
424 BN-Filo Ebola vaccine regimen in adults in Europe (Ebovac2): a randomised,
425 observer-blind, participant-blind, placebo-controlled, phase 2 trial. *The Lancet*
426 *Infectious Diseases* [Internet]. 2021 Apr [cited 2023 Feb 1];21(4):493–506.
427 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S147330992030476X>
428
- 429 6. Anywaine Z, Barry H, Anzala O, Mutua G, Sirima SB, Eholie S, et al. Safety and
430 immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola
431 vaccination in children and adolescents in Africa: A randomised, placebo-
432 controlled, multicentre Phase II clinical trial. Beeson JG, editor. *PLoS Med*
433 [Internet]. 2022 Jan 11 [cited 2023 Feb 1];19(1):e1003865. Available from:
434 <https://dx.plos.org/10.1371/journal.pmed.1003865>
435
- 436 7. Barry H, Mutua G, Kibuuka H, Anywaine Z, Sirima SB, Meda N, et al. Safety and
437 immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola
438 vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled
439 Phase II clinical trial in Africa. Beeson JG, editor. *PLoS Med* [Internet]. 2021 Oct
440 29 [cited 2023 Feb 1];18(10):e1003813. Available from:
441 <https://dx.plos.org/10.1371/journal.pmed.1003813>
442
- 443 8. Ishola D, Manno D, Afolabi MO, Keshinro B, Bockstal V, Rogers B, et al. Safety
444 and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and
445 MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-

- 446 label, non-randomised stage 1, and a randomised, double-blind, controlled stage
447 2 trial. The Lancet Infectious Diseases [Internet]. 2022 Jan [cited 2023 Feb
448 1];22(1):97–109. Available from:
449 <https://linkinghub.elsevier.com/retrieve/pii/S1473309921001250>
450
- 451 9. Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, et al. Safety
452 and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-
453 Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-
454 blind, controlled trial. The Lancet Infectious Diseases [Internet]. 2022 Jan [cited
455 2023 Feb 1];22(1):110–22. Available from:
456 <https://linkinghub.elsevier.com/retrieve/pii/S1473309921001286>
457
- 458 10. Mutua G, Anzala O, Luhn K, Robinson C, Bockstal V, Anumendem D, et al.
459 Safety and immunogenicity of a 2-dose heterologous vaccine regimen with ad26.
460 Zebov and mva-bn-filo ebola vaccines: 12-month data from a phase 1
461 randomized clinical trial in nairobi, kenya. The Journal of Infectious Diseases
462 [Internet]. 2019 Jun 5 [cited 2023 Feb 1];220(1):57–67. Available from:
463 <https://academic.oup.com/jid/article/220/1/57/5364047>
464
- 465 11. Milligan ID, Gibani MM, Sewell R, Clutterbuck EA, Campbell D, Plested E, et al.
466 Safety and immunogenicity of novel adenovirus type 26– and modified vaccinia
467 ankara–vectored ebola vaccines: a randomized clinical trial. JAMA [Internet].
468 2016 Apr 19 [cited 2023 Feb 1];315(15):1610. Available from:
469 <http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2016.4218>
470
- 471 12. Anywaine Z, Whitworth H, Kaleebu P, Praygod G, Shukarev G, Manno D, et al.
472 Safety and immunogenicity of a 2-dose heterologous vaccination regimen with
473 ad26. Zebov and mva-bn-filo ebola vaccines: 12-month data from a phase 1
474 randomized clinical trial in uganda and tanzania. The Journal of Infectious
475 Diseases [Internet]. 2019 Jun 5 [cited 2023 Feb 1];220(1):46–56. Available from:
476 <https://academic.oup.com/jid/article/220/1/46/5364034>
477
- 478 13. Pasin C, Balelli I, Van Effelterre T, Bockstal V, Solfrosi L, Prague M, et al.
479 Dynamics of the humoral immune response to a prime-boost ebola vaccine:
480 quantification and sources of variation. Heise MT, editor. J Virol [Internet]. 2019
481 Sep 15 [cited 2023 Feb 1];93(18):e00579-19. Available from:
482 <https://journals.asm.org/doi/10.1128/JVI.00579-19>
483
- 484 14. Baiden F, Fleck S, Leigh B, Ayieko P, Tindanbil D, Otieno T, et al. Prevalence of
485 malaria and helminth infections in rural communities in northern Sierra Leone, a
486 baseline study to inform Ebola vaccine study protocols. Luty AJF, editor. PLoS
487 ONE [Internet]. 2022 Jul 6 [cited 2023 Feb 1];17(7):e0270968. Available from:
488 <https://dx.plos.org/10.1371/journal.pone.0270968>
489
- 490 15. Cooper PJ, Espinel I, Paredes W, Guderian RH, Nutman TB. Impaired tetanus-
491 specific cellular and humoral responses following tetanus vaccination in human

- 492 onchocerciasis: a possible role for interleukin-10. J INFECT DIS [Internet]. 1998
493 Oct [cited 2023 Feb 1];178(4):1133–8. Available from:
494 <https://academic.oup.com/jid/article-lookup/doi/10.1086/515661>
495
- 496 16. Sabin EA, Araujo MI, Carvalho EM, Pearce EJ. Impairment of tetanus toxoid-
497 specific th1-like immune responses in humans infected with schistosoma
498 mansoni. The Journal of Infectious Diseases [Internet]. 1996 Jan [cited 2023 Feb
499 1];173(1):269–72. Available from:
500 <https://academic.oup.com/jid/articlelookup/doi/10.1093/infdis/173.1.269>
501
- 502 17. Dzhivhuho GA, Rehrl SA, Ndlovu H, Horsnell WGC, Brombacher F, Williamson
503 AL, et al. Chronic schistosomiasis suppresses HIV-specific responses to DNA-
504 MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment
505 and increases helminth-associated pathology in a mouse model. Silvestri G,
506 editor. PLoS Pathog [Internet]. 2018 Jul 26 [cited 2023 Feb 1];14(7):e1007182.
507 Available from: <https://dx.plos.org/10.1371/journal.ppat.1007182>
508
- 509 18. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, et al.
510 Human infection with *ascaris lumbricoides* is associated with suppression of the
511 interleukin-2 response to recombinant cholera toxin b subunit following
512 vaccination with the live oral cholera vaccine cvd 103-hgr. Petri WA, editor. Infect
513 Immun [Internet]. 2001 Mar [cited 2023 Feb 1];69(3):1574–80. Available from:
514 <https://journals.asm.org/doi/10.1128/IAI.69.3.1574-1580.2001>
515
- 516 19. Borkow G, Bentwich Z. Chronic parasite infections cause immune changes that
517 could affect successful vaccination. Trends in Parasitology [Internet]. 2008 Jun
518 [cited 2023 Feb 1];24(6):243–5. Available from:
519 <https://linkinghub.elsevier.com/retrieve/pii/S1471492208000949>
520
- 521 20. Obuku AE, Asiki G, Abaasa A, Ssonko I, Harari A, van Dam GJ, et al. Effect of
522 *schistosoma mansoni* infection on innate and hiv-1-specific t-cell immune
523 responses in hiv-1-infected ugandan fisher folk. AIDS Research and Human
524 Retroviruses [Internet]. 2016 Jul [cited 2023 Feb 1];32(7):668–75. Available from:
525 <http://www.liebertpub.com/doi/10.1089/aid.2015.0274>
526
- 527 21. De Bruyn G. Cofactors that may influence vaccine responses: Current Opinion in
528 HIV and AIDS [Internet]. 2010 Sep [cited 2023 Feb 1];5(5):404–8. Available from:
529 <http://journals.lww.com/01222929-201009000-00009>
530
- 531 22. Obuku AE, Lugemwa JK, Abaasa A, Joloba M, Ding S et al. HIV specific Th1
532 responses are altered in Ugandans with schistosoma mansoni coinfection
533 Available from: <https://doi.org/10.21203/rs.3.rs-2163560/v1>
534
- 535 23. Muyanja E, Ssemaganda A, Ngauv P, Cubas R, Perrin H, Srinivasan D, et al.
536 Immune activation alters cellular and humoral responses to yellow fever 17D

- 537 vaccine. *J Clin Invest* [Internet]. 2014 Jul 1 [cited 2023 Feb 2];124(7):3147–58.
538 Available from: <http://www.jci.org/articles/view/75429>
539
- 540 24. George VK, Pallikkuth S, Pahwa R, de Armas LR, Rinaldi S, Pan L, et al.
541 Circulating inflammatory monocytes contribute to impaired influenza vaccine
542 responses in HIV-infected participants. *AIDS* [Internet]. 2018 Jun 19 [cited 2023
543 Feb 2];32(10):1219–28. Available from: [https://journals.lww.com/00002030-](https://journals.lww.com/00002030-201806190-00002)
544 [201806190-00002](https://journals.lww.com/00002030-201806190-00002)
545
- 546 25. Hotez PJ, Kamath A. Neglected tropical diseases in sub-saharan africa: review
547 of their prevalence, distribution, and disease burden. Cappello M, editor. *PLoS*
548 *Negl Trop Dis* [Internet]. 2009 Aug 25 [cited 2023 Feb 1];3(8):e412. Available
549 from: <https://dx.plos.org/10.1371/journal.pntd.0000412>
550
- 551 26. Karagiannis-Voules DA, Biedermann P, Ekpo UF, Garba A, Langer E, Mathieu E,
552 et al. Spatial and temporal distribution of soil-transmitted helminth infection in
553 sub-Saharan Africa: a systematic review and geostatistical meta-analysis. *The*
554 *Lancet Infectious Diseases* [Internet]. 2015 Jan [cited 2023 Feb 1];15(1):74–84.
555 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S147330991471004>
556
- 557 27. Loukouri A, Méité A, Kouadio OK, Djè NN, Trayé-Bi G, Koudou BG, et al.
558 Prevalence, intensity of soil-transmitted helminths, and factors associated with
559 infection: importance in control program with ivermectin and albendazole in
560 eastern côte d’ivoire. *Journal of Tropical Medicine* [Internet]. 2019 Mar 24 [cited
561 2023 Feb 1];2019:1–10. Available from:
562 <https://www.hindawi.com/journals/jtm/2019/7658594/>
563
- 564 28. Ouedraogo H, Drabo F, Zongo D, Bagayan M, Bamba I, Pima T, et al.
565 Schistosomiasis in school-age children in Burkina Faso after a decade of
566 preventive chemotherapy. *Bull World Health Organ* [Internet]. 2016 Jan 1 [cited
567 2023 Feb 1];94(1):37–45. Available from:
568 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709800/pdf/BLT.15.161885.pdf/>
569
- 570 29. Mangano VD, Bianchi C, Ouedraogo M, Kabore Y, Corran P, Silva N, et al.
571 Antibody response to *Schistosoma haematobium* and other helminth species in
572 malaria-exposed populations from Burkina Faso. *Acta Tropica* [Internet]. 2020
573 May [cited 2023 Feb 1];205:105381. Available from:
574 <https://linkinghub.elsevier.com/retrieve/pii/S0001706X19303584>
575
- 576 30. Sang HC, Muchiri G, Ombok M, Odiere MR, Mwinzi PN. *Schistosoma*
577 *haematobium* hotspots in south Nyanza, western Kenya: prevalence, distribution
578 and co-endemicity with *Schistosoma mansoni* and soil-transmitted helminths.
579 *Parasit Vectors* [Internet]. 2014 [cited 2023 Feb 1];7(1):125. Available from:
580 <http://parasitesandvectors.biomedcentral.com/articles/10.1186/1756-3305-7-125>
581

- 582 31. Chadeka EA, Nagi S, Sunahara T, Cheruiyot NB, Bahati F, Ozeki Y, et al. Spatial
583 distribution and risk factors of *Schistosoma haematobium* and hookworm
584 infections among schoolchildren in Kwale, Kenya. Liang S, editor. PLoS Negl
585 Trop Dis [Internet]. 2017 Sep 1 [cited 2023 Feb 1];11(9):e0005872. Available
586 from: <https://dx.plos.org/10.1371/journal.pntd.0005872>
587
- 588 32. Exum NG, Kibira SPS, Ssenyonga R, Nobili J, Shannon AK, Ssempebwa JC, et
589 al. The prevalence of schistosomiasis in Uganda: A nationally representative
590 population estimate to inform control programs and water and sanitation
591 interventions. Akullian A, editor. PLoS Negl Trop Dis [Internet]. 2019 Aug 14
592 [cited 2023 Feb 1];13(8):e0007617. Available from:
593 <https://dx.plos.org/10.1371/journal.pntd.0007617>
594
- 595 33. Bah YM, Paye J, Bah MS, Conteh A, Saffa S, Tia A, et al. Schistosomiasis in
596 school age children in sierra leone after 6 years of mass drug administration with
597 praziquantel. Front Public Health [Internet]. 2019 Feb 12 [cited 2023 Feb 1];7:1.
598 Available from: <https://www.frontiersin.org/article/10.3389/fpubh.2019.00001/full>
599
- 600 34. Pilger D, Heukelbach J, Diederichs A, Schlosser B, Pereira Leite Costa Araújo C,
601 Keyzers A, et al. Anemia, leukocytosis and eosinophilia in a resource-poor
602 population with helmintho-ectoparasitic coinfection. J Infect Dev Ctries [Internet].
603 2010 Nov 10 [cited 2023 Feb 2];5(04):260–9. Available from:
604 <https://jidc.org/index.php/journal/article/view/21537067>
605
- 606 35. Cunnington AJ, Riley EM. Suppression of vaccine responses by malaria:
607 insignificant or overlooked? Expert Review of Vaccines [Internet]. 2010 Apr [cited
608 2023 Feb 7];9(4):409–29. Available from:
609 <http://www.tandfonline.com/doi/full/10.1586/erv.10.16>
610
- 611 36. Zimmermann P, Curtis N. Factors that influence the immune response to
612 vaccination. Clin Microbiol Rev [Internet]. 2019 Mar 20 [cited 2023 Feb 7];32(2):
613 e00084-18. Available from: <https://journals.asm.org/doi/10.1128/CMR.00084-18>
614
- 615 37. Williamson WA, Greenwood BM. Impairment of the immune response to
616 vaccination after acute malaria. The Lancet [Internet]. 1978 Jun [cited 2023 Feb
617 7];311(8078):1328–9. Available from:
618 <https://linkinghub.elsevier.com/retrieve/pii/S0140673678924030>
619
- 620
- 621 38. Ishola D, The EBOVAC-Salone Malaria Infection (MALI) Sub-Study Team, Bah
622 OM, Bangalie FS, Bangura A, David I, et al. Asymptomatic malaria infection and
623 the immune response to the 2-dose ad26. Zebov, Mva-bn-filo Ebola vaccine
624 regimen in adults and children. Clinical Infectious Diseases [Internet]. 2022 Oct
625 29 [cited 2023 Feb 7];75(9):1585–93. Available from:
626 <https://academic.oup.com/cid/article/75/9/1585/6595436>

- 627
628 39. Rizzardini G, Piconi S, Ruzzante S, Fusi ML, Lukwiya M, Declich S, et al.
629 Immunological activation markers in the serum of African and European HIV-
630 seropositive and seronegative individuals: AIDS [Internet]. 1996 Nov [cited 2023
631 Jun 2];10(13):1535–42. Available from: [http://journals.lww.com/00002030-
632 199611000-00012](http://journals.lww.com/00002030-199611000-00012)
633
634 40. Quinn TC, Piot P, McCormick JB, Feinsod FM, Taelman H, Kapita B, Stevens W,
635 Fauci AS. Serologic and immunologic studies in patients with AIDS in North
636 America and Africa. The potential role of infectious agents as cofactors in Human
637 Immunodeficiency Virus infection. JAMA. 1987 May 15; 257(19):2617-21.
638
639 41. Redd AD, Dabirao D, Bream JH, Charvat B, Laeyendecker O, Kiwanuka N, et al.
640 Microbial translocation, the innate cytokine response, and HIV-1 disease
641 progression in Africa. Proc Natl Acad Sci USA [Internet]. 2009 Apr 21 [cited 2023
642 Jun 2];106(16):6718–23. Available from:
643 <https://pnas.org/doi/full/10.1073/pnas.0901983106>
644
645 42. Zimmermann P. The immunological interplay between vaccination and the
646 intestinal microbiota. npj Vaccines [Internet]. 2023 Feb 23 [cited 2023 Jun
647 2];8(1):24. Available from: <https://www.nature.com/articles/s41541-023-00627-9>
648
649

650

651

652

653

654

655

656

657

658

659

660 **Supporting information**

661

662 **Appendix 1: Helminth ELISA commercial kits**

663 **Table S1. Description of the helminth ELISA commercial kits used, measured parasitic**
664 **infection and cross reactivity**

665 **Appendix 2: Sample Size Calculation**

666 **Table S2: Overview of the substudy available sample selection by study (EBL2001,**
667 **EBL2002, EBL3001), age group and country.**

668 **Appendix 3: Description of helminth ELISA test results in the population**

669 **Table S3: Helminth ELISA test results at baseline among all participants of the helminth**
670 **substudy (EBL2001, EBL2002, EBL3001 pooled).**

671 **Table S4: Characteristics of participants (pooled EBL2001, EBL2002, 3001) by helminth**
672 **ELISA test result**

673 **Table S5: Description of helminth ELISA test results in pooled EBL2001, EBL2002 and**
674 **EBL3001 studies**

675 **Appendix 4: Eosinophil levels at baseline**

676 **Table S6: Description of eosinophil levels among participants from studies EBL2001,**
677 **EBL2002 and EBL3001**

678 **Table S7: Description of eosinophil levels by any helminth ELISA test among participants**
679 **from studies EBL2001 and EBL2002**

680 **Table S8: Description of eosinophil levels in participants with any Helminth positive**
681 **ELISA test from EBL2001 and EBL2002 studies (N= 55)**

682 **Figure S1: Description of the EBOV-GP antibodies at 21 days post dose 2 by eosinophil**
683 **count**

684 **Appendix 5: Inflammatory markers**

685 **Figure S2: Correlation between EBOV GP binding antibody geometric mean**
686 **concentrations (GMC) and inflammatory markers**

687 **Figure S3: Inflammatory markers (pg/mL) measured at baseline significantly associated**
688 **with helminth test positivity (0 = No positive helminth ELISA test; 1 = any positive**
689 **helminth ELISA test).**


690 **Figure S4: Inflammatory markers (pg/mL) statistically different between studies**
691 **(EBL2001, EBL2002, EBL3001) at baseline.**

692 **Appendix 6: Analysis of EBOV GP antibody concentration at 21 days post dose 2 and 365**
693 **days post dose 1.**

694 **Table S9: Robustness analyses with each helminth ELISA test separately evaluated as**
695 **independent variables at 21 days post dose 2**

696 **Table S10: Robustness analyses with each helminth ELISA test separately evaluated as an**
697 **as independent variable at 365 days post dose 1**
698 **Figure S5: Comparison of EBOV-GP antibody geometric mean concentration (log10**
699 **transformed) 21 days post dose 2 by any helminth ELISA test result at baseline in pooled**
700 **EBL2001, EBL2002, EBL3001 participants**

medRxiv preprint doi: <https://doi.org/10.1101/2023.07.06.23292287>; this version posted July 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).



Figure